Clinical response with ELMIRON® may require 3 to 6 months of continuous therapy, and patients—like those in the video presentation below—understandably have questions about treatment, additional options, and cost. By clicking on each of the patients in the video, you can learn about the materials and programs Ortho Women's Health & Urology™ has developed to answer those questions.
Important Safety Information
- Contraindications: ELMIRON® is contraindicated in patients with known hypersensitivity to the drug, structurally related compounds, or excipients
- Anticoagulant Activity: ELMIRON® is a weak anticoagulant (blood thinner) which may increase bleeding. Patients undergoing invasive surgery or having signs/symptoms of underlying coagulopathy or other increased risk of bleeding (due to anticoagulant therapy or high doses of anti-inflammatory drugs) should be evaluated for the risk of hemorrhage
- Alopecia: In clinical trials of ELMIRON®, alopecia began within the first 4 weeks of treatment. Ninety-seven percent (97%) of the cases of alopecia reported were alopecia areata, limited to a single area on the scalp
- Use in Pregnancy: ELMIRON® is a Pregnancy Category B drug
- Most Common Adverse Reactions (frequency 1% to 4%): Alopecia (4%), diarrhea (4%), nausea (4%), headache (3%), rash (3%), dyspepsia (2%), abdominal pain (2%), liver function abnormalities (1%), dizziness (1%)